Findings from 3 proof-of-concept studies have been published evaluating the efficacy and safety of carisbamate, a novel neurotherapeutic agent, in the treatment of neuropathic pain. Studies were conducted with patients having postherpetic neuralgia or diabetic peripheral neuropathy for up to 15 weeks. Carisbamate, though well tolerated, did not demonstrate efficacy in neuropathic pain; neither did the active comparator in study 3, pregabalin. READ MORE
Source:Â World Institute of Pain